Cara Therapeutics


Developing proprietary compounds to treat pain, inflammation and pruritus (itching) without inducing many of the side effects associated with current therapies.  These products selectively target the body’s peripheral kappa opioid receptors.  Cara is also developing cannabinoid receptor agonsist that selectively modulate peripheral cannabinoid receptors without targeting CNS cannabinoid receptors.

Stamford CT
United States